

Parasympathetic System in Heart Failure: A Case Series

Mohamed Ztati*, Soumia Elghouzi, Mustapha El Hattou

Cardiology and vascular disease department of Mohamed VI university hospital, Marrakech, Morocco

*Corresponding author: Ztati Mohamed

| Received: 06-05.2019 | Accepted: 13.05.2019 | Published: 21.05.2019

DOI: [10.21276/sjams.2019.7.5.8](https://doi.org/10.21276/sjams.2019.7.5.8)

Abstract

Original Research Article

In heart failure, it has been recognized that the sympathetic nervous system (SNS) is activated, with imbalance of its activity leading to vagal interactions. Measuring vagal response as a daily practice in heart failure patients would be challenging. The aim of this study is to report the vagal response. We conducted a prospective study including a group of symptomatic cardiac failure subjects with ejection fraction EF <40% with sinus rhythm, able to perform the deep breathing and Valsalva test. All of them had clinical examination, ECG, echocardiography and evaluation of autonomic nervous system function. The results obtained were analyzed using SPSS software. We included 100 patients; their mean age was 54 years. The exploration of the autonomic nervous system in our patients was based essentially on two tests which are the deep breathing and the Valsalva maneuver. The results showed a vagal deficit among 80% of our patients with deep breathing test and 69% with the Valsalva maneuver. This results objectified a significant vagal deficiency response. Furthermore, it has recently been demonstrated that vagal stimulation has beneficial effects on heart failure patients.

Keywords: Vagal nerve, heart failure, deficiency.

Copyright © 2019: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

INTRODUCTION

Patients with chronic heart failure (HF) have features of autonomic dysfunction characterized by excessive sympathetic activation and concomitant parasympathetic withdrawal. Autonomic imbalance, which manifests as a reduction of heart rate [HR], variability and baroreflex sensitivity, is associated with worsening HF and an increased risk of mortality independently of ejection fraction and ventricular arrhythmias. Vagal stimulation, a very new promising management of heart failure is under investigation. Measuring vagal response as a daily practice in cardiac failure patients would be interesting. The objective of this study is to report the vagal response amongst heart failure patients.

METHODS

We conducted a prospective study including a group of symptomatic cardiac failure subjects with ejection fraction EF <45% with sinus rhythm. All of them had clinical examination based on heart rate and blood pressure, ECG, echocardiography, deep breathing test (that will evaluate changes in the instant heart rate by deep breathing at a rhythm of 6 breaths/mn performed in a supine position) and Valsalva maneuver (consisting on a forced expiration against a closed glottis which leads to changes in intrathoracic pressure). The results

obtained were analyzed using SPSS software.

RESULTS

We included 100 patients; extreme ages were ranging from 16 to 89 years, with a mean age of 54 years [figure 1]. Sex ratio was 1.9 with 66% of women and 34% of men [figure 2].

Associated cardiovascular risk factors noted were chronic smoking (34% of the cases), followed by sedentary (32% of the cases), 29% of the cases of android obesity, 28% of patients suffered from diabetes, 26% of the cases from high blood pressure and 19% of the cases had dyslipidemia. However, we didn't notice any of an inherited coronary artery disease [figure 3].

According to the NYHA classification of dyspnea, 13 patients had class I, 45 patients had class II, 31 patients had class III, and 12 patients had class IV.

In our series, acute decompensated heart failure was found in 59 patients, while 41 patients had a compensated heart failure. 61 patients showed no signs of HF, 12 patients showed signs of right-sided HF, and 14 patients had signs of congestive HF [figure 4]. Heart failure was complicated with ischemic heart disease in 42 cases, followed by valvulopathies in 26 cases

[figure5]. The exploration of the autonomic nervous system in our patients was based essentially in two tests, the deep breathing test and the Valsalva maneuver [Table 1].

the 36 patients that were under 50 years, 27 ones had a vagal deficiency. For the rest of the patients (64 aged more than 50 years), 28 had a vagal deficiency. Coming to the Valsalva maneuver, its p value below 1.21 is considered abnormal with a vagal deficit in 69% in our patients [figure 6].

Concerning the deep breathing test, amongst

Table-1: Vagal reponse to the deep breathing test

	Vagal deficiency	Normal response (Ratio>1,2)	Total
Age < 50 years	27	9	36
	Vagal deficiency	Normal response (Ratio>1,1)	Total
Age > 50 years	28	36	64




Fig-1: Patient distribution by Age




Fig-2: Patient Distribution by sex




Fig-3: Distribution of cardiovascular risk factors




Fig-4: Ejection fraction in our patients




Fig-5: Etiology of heart failure




Fig-6: Vagal response to the Valsalva maneuver

DISCUSSION

These results have shown a significant vagal deficiency response in cardiac failure patients, and this concurs with the study conducted N.Mouine who included 34 patients, 10 patients [group 1] compared to 24 patients [group 2]. Preliminary results showed vagal response of $7,8 \pm 1,7\%$ in group 1 versus $27 \pm 7,4\%$ in group 2 [$p < 0,05$] [1].

Parasympathetic control of the heart via the vagus nerve is the primary mechanism that regulates beat-to-beat control of heart rate [2]. Additionally, the vagus nerve exerts significant effects at the AV node, as well as effects on both atrial and ventricular myocardium. Vagal control is abnormal in heart failure, occurring at early stages of left ventricular dysfunction, and this reduced vagal function is associated with worse outcomes in patients following myocardial infarction and with heart failure. While central control

mechanisms are abnormal, one of the primary sites of attenuated vagal control is at the level of the parasympathetic ganglion [3]. It remains to be seen whether or not preventing or treating abnormal vagal control of the heart improves prognosis [4].

Acute myocardial ischemia represents a very useful model for a clear representation of what may appear as a complex relationship between sympathetic and vagal activity [5]. The sensory endings of both vagal and sympathetic afferent fibers are mechanoreceptors and are thereby stimulated by the mechanical stretching associated with cardiac dilatation. Indeed, when the heart dilates, vagal and sympathetic afferent cardiac fibers increase their firing, and this afferent sympathetic excitation leads to the tonic and reflex inhibition of cardiac vagal efferent activity [2].

This phenomenon can be expected to occur whenever the heart dilates in heart failure probably due to the systolic dysfunction. In cases of diastolic dysfunction in which the heart does not dilate, the mechanisms in which the vagal activity is reduced have not been fully determined. The study failed to demonstrate an improvement in left ventricle remodeling [LV] parameters, LV function, or circulating biomarkers following 6 months of chronic vagal stimulation [VNS] at the prescribed stimulation settings [11].

NECTAR-HF did however demonstrate significant improvements in the subjective endpoints of NYHA functional class and heart failure related quality-of-life measures [12-14]. Chronic beta-blocker therapy improves left ventricular performance and reverses left ventricular remodeling, reduces risk of hospitalization, and improves survival [6-8]. We must recognize that heart failure is a complex syndrome with an autonomic nervous system dysfunction, and that the autonomic imbalance with the activation of SNS and the reduction in vagal activity should be focused more in the aspects of treatment of heart failure. In this aspect, conservative pharmacological therapy is not sufficient, and device therapy and/or non-pharmacological therapy (exercise training, Waon-therapy) are necessary [5, 9, 10].

CONCLUSION

These results showed a significant vagal deficiency response in cardiac failure. It has been recognized that autonomic nervous system dysfunction occurs. In the treatment of heart failure, the inhibition of the activated SNS, such as with beta-blockers and/or exercise training is important. Furthermore, it has recently been demonstrated that vagal stimulation has beneficial effects on heart failure.

Authors' contributions

All the authors contributed to the writing of this manuscript

REFERENCES

1. Mouine N, Loudiyi N, El Bakkali M, Coghlan L, El Minaoui M, Abouddar S, Benjelloun H. vagal deficiency in cardiac failure: role of deep breathing test: p1143. *European Journal of Heart Failure*. 2016 May 1;18:273.
2. Schwartz PJ, De Ferrari GM. Sympathetic–parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. *Heart failure reviews*. 2011 Mar 1;16(2):101-7.
3. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 Guidelines for the Evaluation and Management of Heart Failure). *Journal of the American College of Cardiology*. 2005 Sep 20;46(6):1116-43.
4. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. *Circulation*. 2005 Oct 18;112(16):2426-35.
5. Kuwahata S, Miyata M, Fujita S, Kubozono T, Shinsato T, Ikeda Y, Hamasaki S, Kuwaki T, Tei C. Improvement of autonomic nervous activity by Waon therapy in patients with chronic heart failure. *Journal of cardiology*. 2011 Jan 1;57(1):100-6.
6. Adams V, Doring C, Schuler G. Impact of physical exercise on alterations in the skeletal muscle in patients with chronic heart failure. *Front Biosci*. 2008 Jan 1;13(1):302-11.
7. Sabbah HN, Imai M, Zaretsky A, Rastogi S, Wang M, Jiang A, Zaca V. 509 Therapy with Vagus nerve electrical stimulation combined with beta-blockade improves left ventricular systolic function in dogs with heart failure beyond that seen with beta-blockade alone. *European Journal of Heart Failure Supplements*. 2007 Jun;6:114-.
8. Zhang Y, Popovic ZB, Bibevski S, Fakhry I, Sica DA, Van Wagoner DR, Mazgalev TN. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. *Circulation: Heart Failure*. 2009 Nov 1;2(6):692-9.
9. Schwartz PJ, De Ferrari GM, Sanzo A, Landolina M, Rordorf R, Raineri C, Campana C, Revera M, Ajmone-Marsan N, Tavazzi L, Odero A. Long term vagal stimulation in patients with advanced heart failure First experience in man. *European journal of heart failure*. 2008 Sep;10(9):884-91.

10. De Ferrari GM, Crijns HJ, Borggrefe M, Milasinovic G, Smid J, Zabel M, Gavazzi A, Sanzo A, Dennert R, Kuschyk J, Raspopovic S. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. *European heart journal*. 2010 Oct 28;32(7):847-55.
11. Kishi T. Heart failure as an autonomic nervous system dysfunction. *Journal of cardiology*. 2012 Mar 1;59(2):117-22.
12. DeGiorgio CM, Schachter SC, Handforth A, Salinsky M, Thompson J, Uthman B, Reed R, Collin S, Tecoma E, Morris GL, Vaughn B. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. *Epilepsia*. 2000 Sep;41(9):1195-200.
13. Zhang Y, Popovic ZB, Bibevski S, Fakhry I, Sica DA, Van Wagoner DR, Mazgalev TN. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. *Circulation: Heart Failure*. 2009 Nov 1;2(6):692-9.
14. Hamann JJ, Ruble SB, Stolen C, Wang M, Gupta RC, Rastogi S, Sabbah HN. Vagus nerve stimulation improves left ventricular function in a canine model of chronic heart failure. *European journal of heart failure*. 2013 Dec;15(12):1319-26.